Few and Far Between: How HIV May Be Evading Antibody Avidity

Overview

Journal PLoS Pathog

Specialty Microbiology

Date 2010 Jun 5

PMID 20523901

Citations 181

Authors

Joshua S Klein

Pamela J Bjorkman

Affiliations

Soon will be listed here.

Citing Articles

The molecular reach of antibodies crucially underpins their viral neutralisation capacity.

Huhn A, Nissley D, Wilson D, Kutuzov M, Donat R, Tan T Nat Commun. 2025; 16(1):338.

PMID: 39746910 PMC: 11695720. DOI: 10.1038/s41467-024-54916-5.

The consequences of SARS-CoV-2 within-host persistence.

Sigal A, Neher R, Lessells R Nat Rev Microbiol. 2024; .

PMID: 39587352 DOI: 10.1038/s41579-024-01125-y.

Intra-channel bi-epitopic crosslinking unleashes ultrapotent antibodies targeting Na1.7 for pain alleviation.

Zhang Y, Ding Y, Zeng Z, Zhu R, Zheng P, Fan S Cell Rep Med. 2024; 5(11):101800.

PMID: 39461335 PMC: 11604545. DOI: 10.1016/j.xcrm.2024.101800.

Antiretroviral Therapy with Ritonavir-Boosted Atazanavir- and Lopinavir-Containing Regimens Correlates with Diminished HIV-1 Neutralization.

Yuste E, Gil H, Garcia F, Sanchez-Merino V Vaccines (Basel). 2024; 12(10).

PMID: 39460342 PMC: 11511486. DOI: 10.3390/vaccines12101176.

Exploring HIV-1 Maturation: A New Frontier in Antiviral Development.

McGraw A, Hillmer G, Medehincu S, Hikichi Y, Gagliardi S, Narayan K Viruses. 2024; 16(9).

PMID: 39339899 PMC: 11437483. DOI: 10.3390/v16091423.

References

Yamaguchi M, Danev R, Nishiyama K, Sugawara K, Nagayama K . Zernike phase contrast electron microscopy of ice-embedded influenza A virus. J Struct Biol. 2008; 162(2):271-6. DOI: 10.1016/j.jsb.2008.01.009. View

Luftig M, Mattu M, Di Giovine P, Geleziunas R, Hrin R, Barbato G . Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nat Struct Mol Biol. 2006; 13(8):740-7. DOI: 10.1038/nsmb1127. View

Scheid J, Mouquet H, Feldhahn N, Seaman M, Velinzon K, Pietzsch J . Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009; 458(7238):636-40. DOI: 10.1038/nature07930. View

Yang X, Kurteva S, Ren X, Lee S, Sodroski J . Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J Virol. 2005; 79(19):12132-47. PMC: 1211524. DOI: 10.1128/JVI.79.19.12132-12147.2005. View

Zhang M, Xiao X, Sidorov I, Choudhry V, Cham F, Zhang P . Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol. 2004; 78(17):9233-42. PMC: 506938. DOI: 10.1128/JVI.78.17.9233-9242.2004. View

Moore J, Sodroski J . Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol. 1996; 70(3):1863-72. PMC: 190014. DOI: 10.1128/JVI.70.3.1863-1872.1996. View

Huang C, Lam S, Acharya P, Tang M, Xiang S, Hussan S . Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science. 2007; 317(5846):1930-4. PMC: 2278242. DOI: 10.1126/science.1145373. View

Layne S, Merges M, Dembo M, Spouge J, Conley S, Moore J . Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology. 1992; 189(2):695-714. DOI: 10.1016/0042-6822(92)90593-e. View

Wolbank S, Kunert R, Stiegler G, Katinger H . Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. J Virol. 2003; 77(7):4095-103. PMC: 150633. DOI: 10.1128/jvi.77.7.4095-4103.2003. View

10.

Dolin R . HIV vaccine trial results--an opening for further research. N Engl J Med. 2009; 361(23):2279-80. DOI: 10.1056/NEJMe0909972. View

11.

West Jr A, Galimidi R, Foglesong C, Gnanapragasam P, Huey-Tubman K, Klein J . Design and expression of a dimeric form of human immunodeficiency virus type 1 antibody 2G12 with increased neutralization potency. J Virol. 2008; 83(1):98-104. PMC: 2612297. DOI: 10.1128/JVI.01564-08. View

12.

Wyatt R, Desjardin E, Olshevsky U, Nixon C, Binley J, Olshevsky V . Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein. J Virol. 1997; 71(12):9722-31. PMC: 230282. DOI: 10.1128/JVI.71.12.9722-9731.1997. View

13.

Chertova E, Bess Jr J, Crise B, Sowder II R, Schaden T, Hilburn J . Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol. 2002; 76(11):5315-25. PMC: 137021. DOI: 10.1128/jvi.76.11.5315-5325.2002. View

14.

Bongini L, Fanelli D, Piazza F, De Los Rios P, Sanner M, Skoglund U . A dynamical study of antibody-antigen encounter reactions. Phys Biol. 2007; 4(3):172-80. DOI: 10.1088/1478-3975/4/3/004. View

15.

Tomaras G, Yates N, Liu P, Qin L, Fouda G, Chavez L . Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol. 2008; 82(24):12449-63. PMC: 2593361. DOI: 10.1128/JVI.01708-08. View

16.

Edwards M, Dimmock N . Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event. J Virol. 2001; 75(21):10208-18. PMC: 114595. DOI: 10.1128/JVI.75.21.10208-10218.2001. View

17.

Sougrat R, Bartesaghi A, Lifson J, Bennett A, Bess J, Zabransky D . Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. PLoS Pathog. 2007; 3(5):e63. PMC: 1864992. DOI: 10.1371/journal.ppat.0030063. View

18.

Mattes M . Binding parameters of antibodies: pseudo-affinity and other misconceptions. Cancer Immunol Immunother. 2005; 54(6):513-6. PMC: 11032981. DOI: 10.1007/s00262-004-0644-3. View

19.

Labrijn A, Poignard P, Raja A, Zwick M, Delgado K, Franti M . Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol. 2003; 77(19):10557-65. PMC: 228502. DOI: 10.1128/jvi.77.19.10557-10565.2003. View

20.

Diskin R, Marcovecchio P, Bjorkman P . Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Nat Struct Mol Biol. 2010; 17(5):608-13. PMC: 2949298. DOI: 10.1038/nsmb.1796. View